Stephanie M Davis1, Melissa A Habel1, Carel Pretorius2, Teng Yu2, Carlos Toledo1, Timothy Farley3, Geoffrey Kabuye4, Julia Samuelson5. 1. Division of Global HIV/AIDS and Tuberculosis, Centers for Disease Control and Prevention, Atlanta, GA. 2. Modeling, Planning and Policy Analysis Center of Excellence, Avenir Health, Glastonbury, CT. 3. Sigma3 Services SÀRL, Nyon, Switzerland. 4. Centers for Disease Control and Prevention, Kampala, Uganda; and. 5. Department of HIV, AIDS and Hepatitis; Key Populations and Innovative Prevention Team, World Health Organization, Geneva, Switzerland.
Abstract
BACKGROUND: In addition to providing millions of men with lifelong lower risk for HIV infection, voluntary medical male circumcision (VMMC) also provides female partners with health benefits including decreased risk for human papillomavirus (HPV) and resultant cervical cancer (CC). SETTING: We modeled potential impacts of VMMC on CC incidence and mortality in Uganda as an additional benefit beyond HIV prevention. METHODS: HPV and CC outcomes were modeled using the CC model from the Spectrum policy tool suite, calibrated for Uganda, to estimate HPV infection incidence and progression to CC, using a 50-year (2018-2067) time horizon. 2016 Demographic Health Survey data provided baseline VMMC coverage. The baseline (no VMMC scale-up beyond current coverage, minimal HPV vaccination coverage) was compared with multiple scenarios to assess the varying impact of VMMC according to different implementations of HPV vaccination and HPV screening programs. RESULTS: Without further intervention, annual CC incidence was projected to rise from 16.9 to 31.2 per 100,000 women in 2067. VMMC scale-up alone decreased 2067 annual CC incidence to 25.3, averting 13,000 deaths between 2018 and 2067. With rapidly-achieved 90% HPV9 vaccination coverage for adolescent girls and young women, 2067 incidence dropped below 10 per 100,000 with or without a VMMC program. With 45% vaccine coverage, the addition of VMMC scaleup decreased incidence by 2.9 per 100,000 and averted 8000 additional deaths. Similarly, with HPV screen-and-treat without vaccination, the addition of VMMC scaleup decreased incidence by 5.1 per 100,000 and averted 10,000 additional deaths. CONCLUSIONS: Planned VMMC scale-up to 90% coverage from current levels could prevent a substantial number of CC cases and deaths in the absence of rapid scale-up of HPV vaccination to 90% coverage.
BACKGROUND: In addition to providing millions of men with lifelong lower risk for HIV infection, voluntary medical male circumcision (VMMC) also provides female partners with health benefits including decreased risk for human papillomavirus (HPV) and resultant cervical cancer (CC). SETTING: We modeled potential impacts of VMMC on CC incidence and mortality in Uganda as an additional benefit beyond HIV prevention. METHODS: HPV and CC outcomes were modeled using the CC model from the Spectrum policy tool suite, calibrated for Uganda, to estimate HPV infection incidence and progression to CC, using a 50-year (2018-2067) time horizon. 2016 Demographic Health Survey data provided baseline VMMC coverage. The baseline (no VMMC scale-up beyond current coverage, minimal HPV vaccination coverage) was compared with multiple scenarios to assess the varying impact of VMMC according to different implementations of HPV vaccination and HPV screening programs. RESULTS: Without further intervention, annual CC incidence was projected to rise from 16.9 to 31.2 per 100,000 women in 2067. VMMC scale-up alone decreased 2067 annual CC incidence to 25.3, averting 13,000 deaths between 2018 and 2067. With rapidly-achieved 90% HPV9 vaccination coverage for adolescent girls and young women, 2067 incidence dropped below 10 per 100,000 with or without a VMMC program. With 45% vaccine coverage, the addition of VMMC scaleup decreased incidence by 2.9 per 100,000 and averted 8000 additional deaths. Similarly, with HPV screen-and-treat without vaccination, the addition of VMMC scaleup decreased incidence by 5.1 per 100,000 and averted 10,000 additional deaths. CONCLUSIONS: Planned VMMC scale-up to 90% coverage from current levels could prevent a substantial number of CC cases and deaths in the absence of rapid scale-up of HPV vaccination to 90% coverage.
Authors: Virginia Senkomago; Danielle M Backes; Michael G Hudgens; Charles Poole; Kawango Agot; Stephen Moses; Peter J F Snijders; Chris J L M Meijer; Albertus T Hesselink; Nicolas F Schlecht; Robert C Bailey; Jennifer S Smith Journal: J Infect Dis Date: 2014-09-26 Impact factor: 5.226
Authors: Kelley Vanbuskirk; Rachel L Winer; James P Hughes; Qinghua Feng; Yuzo Arima; Shu-Kuang Lee; Michael E Stern; Sandra F O'Reilly; Laura A Koutsky Journal: Sex Transm Dis Date: 2011-11 Impact factor: 2.830
Authors: Sue J Goldie; Daniel Grima; Michele Kohli; Thomas C Wright; Milton Weinstein; Eduardo Franco Journal: Int J Cancer Date: 2003-10-10 Impact factor: 7.396
Authors: Mary K Grabowski; Xiangrong Kong; Ronald H Gray; David Serwadda; Godfrey Kigozi; Patti E Gravitt; Fred Nalugoda; Steven J Reynolds; Maria J Wawer; Andrew D Redd; Stephen Watya; Thomas C Quinn; Aaron A R Tobian Journal: J Infect Dis Date: 2015-11-23 Impact factor: 5.226
Authors: Aaron A R Tobian; David Serwadda; Thomas C Quinn; Godfrey Kigozi; Patti E Gravitt; Oliver Laeyendecker; Blake Charvat; Victor Ssempijja; Melissa Riedesel; Amy E Oliver; Rebecca G Nowak; Lawrence H Moulton; Michael Z Chen; Steven J Reynolds; Maria J Wawer; Ronald H Gray Journal: N Engl J Med Date: 2009-03-26 Impact factor: 91.245
Authors: John Stover; Lori Bollinger; Jose Antonio Izazola; Luiz Loures; Paul DeLay; Peter D Ghys Journal: PLoS One Date: 2016-05-09 Impact factor: 3.240
Authors: Nicole G Campos; Vivien Tsu; Jose Jeronimo; Mercy Mvundura; Kyueun Lee; Jane J Kim Journal: Int J Cancer Date: 2017-03-15 Impact factor: 7.396